anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a moisture-keeping plant extract having the effects of keeping the moisturizing effects for a long period; and to provide a moisture-keeping external preparation, a cosmetic, a bath agent and a detergent composition.  &lt;P&gt;SOLUTION: The moisture-keeping plant extract comprises an extract of a mixture of Zizyphus jujuba Miller var. inermis Rehder, Cinnamomum cassia Blume, Paeonia lactiflora Pallas, Zingiber officinale Rosco, Grycyrrhiza glabra Linne and Astragalus membranaceus Bunge. The moisture-keeping external preparation, the cosmetic, the bath agent and the detergent composition contain the extract. The product obtained by decocting the crude medicines in prescribed proportions has the same composition as the one called Keishikaougito. The extract of the mixture of the crude medicines contains a moisture-keeping component having the moisture-keeping effects lasting for a long period, and is effective for the prevention, reduction and amelioration of dryness of the skin, rough skin, chaps, cracks, scurf, itching, and inflammatory diseases by external use, and also effective for dryness, looseness, split hair, broken hair, gloss impartment, or the like, of the hair.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
FIELD: food industry, fish industry. SUBSTANCE: the present innovation deals with biologically active additives (BAA) obtained out of sea products that could be applied in dietary therapy for either prophylaxis or treating cardiovascular diseases. BAA contains food fish oil and biologically active substances (variants): concentrate of carotinoids, alcoholic extract of phospholipids&#39; concentrate, alcoholic extract of phospholipids&#39; concentrate with saponins obtained out of sea hydrobionts, such as sea cucumbers, sea hedgehogs and starfishes, herring, etc. The present innovation increases biological activity of fish oil, broadens assortment of curative-prophylactic products due to applying wide range of biologically active substances obtained out of hydrobionts. EFFECT: higher efficiency. 3 cl, 3 ex
Biphosphonates and especially disodium pamidronate are becoming more and more important for the therapy of a wide variety of diseases. Pure and stable disodium pamidronate is a prerequisite for the manufacture of the respective pharmaceutical formulations. In the literature, there is a controversy on the stability of the various hydrates of disodium 10 pamidronate. The present invention presents a facile, easy to scale-up method of producing disodium pamidronate pentahydrate of high purity and high stability, at yield &gt;90 %. This method avoids any steps that may introduce impurities. It is based on the fact that pamidronic acid can be transferred into its diammonium salt at high concentration, at room temperature. This highly concentrated solution is converted into the disodium salt via ion-exchange, at conditions that maintain the high concentration. The ion-exchange step simultaneously eliminates any undesired divalent or trivalent cations. The disodium salt can be directly crystallized in the eluate of the ion-exchange column, without the need of further concentration and/or addition of any alcohol, by only lowering the temperature down to 5°C.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a means for ameliorating accumulated damage of the nail sometimes appearing following the use of nail enamel.  &lt;P&gt;SOLUTION: The cosmetic for nail care contains a lavender essential oil. The care of the nail is carried out for a person using the nail enamel by coating the cosmetic to repair the damage of the nail at night. The cosmetic is preferably the one not accompanying wiping operation, and the dosage form is preferably an oil-in-water emulsion type. Preferably a silk protein hydrolyzate is contained therein, and more preferably phytosterol is contained therein.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
This invention is to provide dissolved electrolytic hydrogen containing water, which prevents or inhibiting DNA damage. Purified water is obtained from tap water and NaCl is added to justify the conductivity bigger than 100 mu S/cm. Then, electrolysis is applied. The obtained cathode water is output and neutralized. The obtained cathode water includes dissolved hydrogen (H&lt;SP&gt;+&lt;/SP&gt;, H., H2) of at least 0.1 ppm. This dissolved hydrogen prevents or inhibits DNA damage.
FIELD: food-production industry. SUBSTANCE: this relates to food additives intended for restoring and maintaining normal vital activity of digestive organs of man. Composition of food additive &#34;Sorbvit&#34; includes following ingredients: alimentary wheat bran - 3 weight parts, brewer&#39;s barley malt - 1 weight part, nettle leaf - 1 weight part. Aforesaid ingredients are mixed together for producing homogeneous mass. Aforesaid proportioning of components allows for producing optimal combination of vitamins, micro elements, and biostimulators in biologically balanced condition. Aforesaid additive ensures simultaneous sorbing of harmful materials and vitaminization organism of man. EFFECT: higher efficiency.
This is a multicenter, cross-sectional study involving 200 consecutive patients with a diagnosis of idiopathic PD.

We will collect demographic data such as age, sex and education, and clinical features encompassing age at onset, disease duration, antiparkinsonian treatment, and levodopa-equivalent daily dose (LEDD). Patients will undergo a clinical examination in which we will record the Hoehn and Yahr scale (H\&amp;amp;Y) and Movement Disorders Unified Parkinson\&amp;#39;s Disease Rating Scale (MDS-UPDRS) part I-II- III (in ON state) and IV, and Montreal Cognitive Assessment (MoCA). The answers to the NoMoFA will be obtained giving the self-administered questionnaire to patients during regular follow-up visits. The NoMoFA Questionnaire has a total of 27 items with a total maximum possible score for the NoMoFA of 81 points (27 x 3). To evaluate the stability of the Italian version of the NoMoFA (test-retest reliability), a group of 60 patients will repeat the scale 14 days after the first evaluation.

We will establish a translation team composed of movement disorders specialists who are native speakers of the designated language and fluent in English. As word-for-word translations can be misleading, cultural difference between English and Italian will be taken into account. After translation, a different independent group with same competencies of the first translating team will perform a back-translation. The back-translated version of the rating scale will be compared to the original English version. The translation and back-translation team members in a revised document will fully resolve unclear concepts or ambiguities between the original and back-translated English editions. Before the validation phase, a so-called 'cognitive pretesting' will be performed by submitting the provisional translated scale to 10 PD patients by 2 evaluators external to the translator team. Then, evaluators\&amp;#39; and subjects\&amp;#39; responses will be integrated into the revisions and retested until all major problems are resolved. Once the translation and cognitive pretesting stages are completed, the translated scale is field-tested in a sample of native speakers of the language of the translated scale (validation).
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a cosmetic having a good feeling of use during coating, excellent aesthetic properties as the cosmetic and making a bare skin feeling compatible with covering of skin defects.  &lt;P&gt;SOLUTION: The cosmetic comprises fibers. In the cosmetic, the length of the fibers is 1-150 μm. The fibers have a modified cross section. Furthermore, the fibers have a hollow structure and the fibers are prepared by conjugating two or more kinds of polymers. The fibers have unevennesses of several nm to several tens μm on the surface.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
PCT No. PCT/EP86/00401 Sec. 371 Date Mar. 16, 1987 Sec. 102(e) Date Mar. 16, 1987 PCT Filed Jul. 8, 1986 PCT Pub. No. WO87/00523 PCT Pub. Date Jan. 29, 1987.Tertiary hydroxyalkylxanthines having the general formula (I), characterized by the fact that at least one of the residues R1 and R3 represents a tertiary hydroxyalkyl group of formula (Ia) in which R4 represents an alkyl group having up to 3 carbon atoms and n a whole number from 2 to 5; the other residue which may remain R1 or R3 is a hydrogen atom or an aliphatic hydrocarbon residue R5 having up to 6 carbon atoms, in which the carbon chain may be separated by a maximum of two oxygen atoms or be substituted by an oxo group or two hydroxy groups at the most, and R2 represents an alkyl group with 1 to 4 carbon atoms. Also described is a process for manufacturing these compounds, which are suitable for the manufacture of medicines, in particular for use in the prevention and/or treatment of peripheral and/or cerebral irrigation disorders. &lt;IMAGE&gt; (I)  &lt;IMAGE&gt; (Ia)
Polycarbonate film of 0.002-0.01 mm. thickness is used as insulating film in prepn. of dental prostheses, e.g. between the plaster mould and the paste compsn. Used for making the dental plaste. The very thin film is readily shaped to fit the mould and adheres strongly to the usual methyl methacrylate paste compsnsn. so that laborious removal from the plate, as required when tin-foil is used, is avoided. A smooth, hygienic, easily-cleaned surface is left on the plate, which conforms exactly to the mould shape. Permeation of moisture from the plaster mould into the paste, with adverse effects on the monomer, is prevented. The film is pref. on high-molecular poly- 4,4&#39;-(diphenyl)2,2-propane carbonate and is about 0.003 mm in thickness.
&lt;P&gt;PROBLEM TO BE SOLVED: To realize a medical service processing system enabling extensive time reduction, resource conservation, and safe transfer of data without a modification in the existing work flow.  &lt;P&gt;SOLUTION: A medical record form 1a and a prescription form 1b are prepared upon reception of a patient. The forms 1a, 1b each bears a special pattern drawn therein, to be registered in the database with relevance to the patient established during the preparation process. The instant the physician fills in the record form 1a at a consulting room 100, data about the record and prescription as digitized are transmitted to a medical service center 200. The data about prescription are transmitted also to a dispensing pharmacy 300. Points are counted based on the transmitted data about the record and prescription, and a patient visiting the accountant 400 after examination can pay the fee in next to no time. Prescription is complete when the patient visits the pharmacy 300. The waiting time is reduced to almost none for the patient.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a medical imaging system having a function supporting a user for processing medical image data.  &lt;P&gt;SOLUTION: This method 130 is provided for automatically displaying information during processing medical images. This method 130 includes a process 134 for determining an image view to a display image 126 created from collected scanning data, and a process 136 for determining a text 124 for displaying it associated with a marker 122 to be displayed on the display image 126 based on the determined image view. The text 124 indicates a region specified by the marker 122 in the display image. This method further includes a process 138 for automatically displaying the text 124 determined associated with the marker 122 on the display image 126.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
Preventing or treating neurodegenerative or dementia diseases characterized by molecular pathology of microtubuli-associated tau protein comprises administering a K252a derivative (I). Preventing or treating neurodegenerative or dementia diseases characterized by molecular pathology of microtubuli-associated tau protein comprises administering a K252a derivative (I) of formula 1 or its salt. R1COOR or CONHR; R : H, Me, Et or cyclopropyl; R2, R3H, F, Me, OH, NH2, NHMe or NMe2; and Z : (H,H) or O. Independent claims are also included for: (1) identifying inhibitors of neurofibrillar degeneration and their activity by incubating metabolically active mammalian brain section tissue with candidate compounds at various concentrations, provoking tau hyperphosphorylation with a PP2A (not defined) inhibitor, quantifying tau phosphoepitopes in the tissue or tissue extracts by immunoassay, and comparing the phosphoepitope provocation with that of untreated control tissue; (2) determining a suitable dose of an inhibitor of paired helical filament-like tau hyperphosphorylation for treating a disease characterized by neurofibrillar pathology by titrating the inhibitor in brain sections stimulated with a PP2A inhibitor to determine effective tissue concentrations and pharmacokinetically evaluating a dosage scheme to produce effective concentrations in the CNS of a subject; and (3) determining a suitable dose of an inhibitor of paired helical filament-like tau hyperphosphorylation for treating a disease characterized by neurofibrillar pathology by determining a normal level of a paired helical filament-like tau phosphoepitope in the cerebrospinal fluid of healthy control subjects of the same age group, increasing the dose of an inhibitor in a subject suffering from a form of neurofibrillar degeneration at intervals of several weeks or administering increasing doses of an inhibitor identified as above to individual subjects, immunochemically evaluating the reduction in paired helical filament-like tau phosphoepitope in the cerebrospinal fluid of the same subject immediately before the start of treatment and again after several weeks of continuous administration of the inhibitor, and comparing the level of paired helical filament-like tau phosphoepitope in cerebrospinal fluid before and after the start of treatment of a subject suffering from a form of neurofibrillar degeneration, and determining the effective dose as one that reduces the paired helical filament-like tau phosphoepitope level to the range occurring in healthy controls of the same age group. [Image] ACTIVITY : Neuroprotective; Nootropic; Antiparkinsonian; Cerebroprotective. MECHANISM OF ACTION : Tau hyperphosphorylation inhibitor. 9(S),12(R)-Epoxy-2,3,9,10,11,12-hexahydro-10(R)-amino-9-methyl-1-oxo-1H-diindolo[1,2,3-fg:3&#39;,2&#39;,1&#39;-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxamide had an IC50 of 200 nM for inhibiting phosphorylation of AP422, AT8, AT100 and Thr231 epitopes in rat hippocampus sections, and 400 nM for inhibiting phosphorylation of the Ser262 epitope.
Novel positively-charged prodrugs in a general formula (1) &#39;structure 1&#39; of acetylsalicylic acid and acetylsalicylic acid analogues are designed and synthesized. The compounds of the general formula (1) &#39;structure 1&#39; can be prepared by reacting functional derivatives (for example acid halides or mixed anhydrides) of acetylsalicylic acid or acetylsalicylic acid analogues with suitable alcohols, thiols or amines. The positively-charged amino groups of the pro-drugs not only substantially increase the solubility of the drugs, but also bond to negative charges at the phosphate terminal of biological membranes and push prodrug molecules into the cellular fluid. Experiment results suggest that the prodrug diethylaminoethyl acetylsalicylate-acetate has a human skin penetration speed faster than that of acetylsalicylic acid by nearly 400 times, and faster than that of ethyl acetylsalicylate by nearly 100 times. In plasma, 80% of the prodrug can change back to the drug in a few minutes. The prodrugs can be used medicinally in treating any aspirin-treatable diseases of human or animals and be administered not only orally, but also transdermally for any kind of medical treatments and avoid most of the side effects of acetylsalicylic acid and acetylsalicylic acid analogues, most notably side effects such as dyspepsia, gastroduodenal bleeding, gastric ulcerations and gastritis. A controlled transdermal administration systems of the prodrug enables acetylsalicylic acid and acetylsalicylic acid analogues in the blood to reach constantly optimal therapeutic blood levels to increase curative effect and reduce the side effects of acetylsalicylic acid.
PURPOSE:The titled kneaded liquid, containing aluminum phosphate, sodium chloride and a surfactant, and capable of increasing the strength and fire resistance at high temperatures and improving the surface conditions of a cast material. CONSTITUTION:A kneading liquid of a dental investment material, containing 0.6-6wt% aluminum phosphate, e.g. aluminum primary or secondary phosphate, 0.6-3wt% sodium chloride and 10-100ppm surfactant, e.g. nonionic or anionic surfactant, and having &gt;=1.6pH. The mixing liquid ratio of the kneading liquid to be added to an investment material powder is suitably within 1:(0.2-0.4) range. The mixing of a gypsum based investment material by using the above-mentioned kneading liquid permits the casting of nickel-chromium alloy requiring &gt;=1,300 deg.C temperature, and a prosthesis can be manufactured from the above- mentioned alloy.
Orgateins are isolated from mixtures of soluble proteins using &gt;=1 of the following purification stages (1) an aq. soln of the protein mixture is treated with a protidolytic enzyme which selectively degrades one fraction of the proteins other than orgotein (2) at least the erythrocyte fraction of whole blood is heated at 60-80 degrees C and pH 5-8 to precipitate haemoglobin, the precipitate is separated and orgotein isolated from supernatant liquid (3). A mixture of orgotein and other proteins is dissolved in an aqs. buffer at pH 6 to give a soln of ionic strength 0-01 M and chromatographed on a weakly basic ion exchange resin (e.g. DEAE-cellulose TEAE-cellulose or cross-linked dextran having diethylaminoethyl gps). The resin is selectively eluted with an eluent having greater ionic strength (pref. increased progressively from 0.02 M to &gt;0.03 M) at pH 6 with simultaneous determination of the absorption at 2650 and/or 2800 angstroms and the Cu and/or Zn content of the eluate and separation of the eluate which has a maximum non-ionised metal content and a minimum absorption at 265 or 280 nm. When the soluble protein mixture is obtained from erythrocytes the haemoglobin and carbonic-anhydrase are removed by washing the column prior to the elution of the orgotein.
PURPOSE: To obtain a hair care composition capable of improving a flyaway problem such as fluffing of hairs and a difficulty in adjusting a hair combing, and transparent or not transparent by containing a quaternary silicone polymer. CONSTITUTION: This hair care composition contains at least one kind of a surfactant, a quaternary silicone polymer soluble to the surfactant but not soluble to water and having a terminal functional group and a cationic sedimented polymer as active ingredients. In the composition, 5-40wt.% surfactant, 0.01-1.0wt.% quaternary silicone polymer, 0.01-1wt.% cationic polymer are formulated. The quaternary silicon polymer has &lt;=0.01wt.% solubility to water in 20 deg.C water and 50-120 unit length, and is expressed by the formula (R&lt;1&gt; , R&lt;10&gt; are each H, an alkyl, an alkenyl, etc.; R&lt;2&gt; to R&lt;9&gt; are each H, a lower alkyl, a lower alkenyl, etc.; X is an ion pair).
Oil-in-water compsns. are prepd. by using a generator of shock waves either without an emulsifier or in the presence of 1% surfactant such as a nonionic ethylene oxide condensate. The shock waves are provided by an appts. comprising a generator of superheated water operating continuously in a pulsating manner, the sudden decompression being regulated by a pressostat. Examples specified are in dairy foods made from milk and serum, and cheese coloured with carotene emulsion; also as a fermentation medium for producing amino acids and as a vaccine support; as in polymer emulsions and emulsion polymerisation and in exterior emulsion paints. As they do not require an emulsifier, which contributes some instability to the emulsions, they are more stable. They are stable at &gt;60 degrees C in neutral or basic medium and in acid medium in the presence of a protective colloid.
Systems, methods, and computer storage media are provided for determining a patient&#39;s severity of illness score (pSIS) for a patient admitted to an acute care facility. Data corresponding to physiologic components is received from an electronic medical record associated with a patient admitted to an acute care healthcare facility. The physiologic components include vital sign measurements and laboratory tests. Weights are assigned to a minimum, median, and maximum measured values for each vital sign. Weights are assigned to minimum and maximum values for each laboratory test. The weights are derived based on a deviation from normal within a time period. A pSIS is determined by summing the weights. Additional data corresponding to physiologic components may be received from the electronic medical record. The additional data may be utilized to update the weights and determine a patient&#39;s updated pSIS that may be utilized to track a progress of the patient.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new nucleic acid-delivering means by which the nucleic acid can be efficiently delivered to the interior of a biological cell even by a simple administration such as oral administration.  &lt;P&gt;SOLUTION: The particle for delivering a plasmid is a cyanoacrylate polymer particle including the plasmid. The particle is preferably produced by anion polymerization of a cyanoacylate monomer in the coexistence of the cyanoacrylate monomer, saccharides and the plasmid. The particle can efficiently deliver the plasmid even by the oral administration. The particle can be produced from a material having compatibility with the human body, and thereby has high safety to the human body. As a result, the particle is extremely advantageous in clinical application.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
PURPOSE:To obtain the titled material having a small min. optical density and capable of easily handling at a yellow light by incorporating a specific compd. to an emulsion layer or a hydrophilic colloid layer adjacent to said layer. CONSTITUTION:The emulsion layer of the titled material is composed of the direct positive type silver halide emulsion which is previously fogged. The silver halide contains &gt;=70% silver chloride. The emulsion layer or the hydrophilic colloid layer adjacent to said layer contains &gt;=1 kinds of the compd. shown by the formula. In the formula, Z1 is a nonmetallic atom group necessary to forming a nitrogen-contg. heterocyclic ring, T is halogen atom or alkyl, alkenyl, cyano or hydroxy group, etc., (q) is 1, 2 or 3, (r) is 0, 1 or 2. Thus, the titled material having the low min. optical density and capable of easily handling at a light room which is shined the yellow light or cut the UV ray, is obtd.
PURPOSE:To obtain high-purity hemin at a low cost, by hemolyzing erythrocytes, denaturing and precipitating hemoglobin, adjusting the pH, forming hemin- containing precipitates and extracting the precipitates with an acidic organic solvent. CONSTITUTION:Hemin is produced from erythrocytes. In the process, ery throcytes are hemolyzed and the pH of the resultant hemolyzed solution is adjusted to &lt;=6.5 or &gt;=12 to denature hemoglobin. The pH of the above- mentioned hemolyzed solution is adjusted to 7-8 to form hemin-containing precipitates, which are then separated and extracted with an acidic organic solvent, e.g. methanol or acetone, to dissolve the hemin. Precipitates insoluble in the organic solvent, e.g. protein, etc., are removed and acetic acid is added to distil away the organic solvent and recover the hemin. A small amount of the organic solvent used is sufficient, and the solvent distilled away without containing water therein can be reused.